Jan 5th 2018: CytoDel completes series A financing

Pryor Cashman represented CytoDel, Inc. in connection with a private placement of Series A Convertible Preferred Stock to institutional accredited investors, led by a leading private equity fund that invests in significant scientific discoveries and supports them by providing capital and expertise. The offering closed on January 5, 2018.

January 2021: New strategy to fight world’s most potent poison passes first tests in animals

Tamed botulinum toxin ferries miniature antibodies into nerves to reverse paralysis

January 2021: Decoy toxin harnessed to fight botulism

In animal studies, miniature antibodies work within nerves to reverse paralysis

CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) Published in Science Translational Medicine

New York City, January 6, 2021 – CytoDel, Inc. (“CytoDel” or “the Company”), a privately-held corporation, today announces the publication of preclinical data on the Company’s lead product, Cyto111, in the peer-reviewed journal, Science Translational Medicine. The complete text of the article titled, “Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism,” can be found here.